RECURRENT FALLOPIAN TUBE CANCER

Clinical trials for RECURRENT FALLOPIAN TUBE CANCER explained in plain language.

Never miss a new study

Get alerted when new RECURRENT FALLOPIAN TUBE CANCER trials appear

Sign up with your email to follow new studies for RECURRENT FALLOPIAN TUBE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for Tough-to-Treat gynecologic cancers

Disease control Recruiting now

This study is testing a new drug called ubamatamab, given alone or with another drug (cemiplimab), for people with recurrent ovarian, fallopian tube, peritoneal, or endometrial cancers. The main goals are to find a safe and effective dose and to see if the treatment can shrink tu…

Matched conditions: RECURRENT FALLOPIAN TUBE CANCER

Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control

Last updated Mar 06, 2026 15:37 UTC

RECURRENT FALLOPIAN TUBE CANCER

Get alerted when new RECURRENT FALLOPIAN TUBE CANCER trials appear

New hope for Tough-to-Treat gynecologic cancers